Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3880477 | 0.86 | L3MBTL1 (0.59) | ESR1ESR2L3MBTL1KDM4EIP6K1 | |
| SCHEMBL30898575 | 0.86 | L3MBTL1 (0.59) | ESR1ESR2L3MBTL1KDM4EIP6K1 | |
| SCHEMBL7600928 | 0.81 | L3MBTL1 (0.49) | L3MBTL1KDM4EIP6K1ALDH1A1HPGD | |
| SCHEMBL9919057 | 0.79 | F2RL3 (0.51) | L3MBTL1KDM4EIP6K1ALDH1A1ACVR1 | |
| SCHEMBL5312155 | 0.79 | L3MBTL1 (0.48) | ESR1ESR2L3MBTL1KDM4EIP6K1 | |
| SCHEMBL1500289 | 0.79 | L3MBTL1 (0.48) | ESR1ESR2L3MBTL1KDM4EIP6K1 | |
| SCHEMBL12177224 | 0.79 | L3MBTL1 (0.48) | ESR1ESR2L3MBTL1KDM4EIP6K1 | |
| SCHEMBL30204539 | 0.79 | HCAR3 (0.49) | L3MBTL1KDM4EIP6K1ALDH1A1HPGD | |
| SCHEMBL18434210 | 0.79 | L3MBTL1 (0.44) | ESR1ESR2L3MBTL1KDM4EIP6K1 | |
| SCHEMBL2040732 | 0.79 | HCAR3 (0.49) | L3MBTL1KDM4EIP6K1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522597-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | ESR1 2825/4885ESR2 1662/4885L3MBTL1 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.